Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns
""
Blog |
13 April 2021

The Access Blog

""
We face huge vaccine inequity around the world, with just 0.2% of all vaccines going to low-income countries
Blog
Blog |
26 April 2021
COVID-19

COVID-19 vaccines: Recommendations for equitable access

At MSF’s post-operative care hospital in Mosul (Iraq), infection and prevention control (IPC) measures are implemented. One of the pillars of IPC consists in cleaning, sterilizing and sanitizing. Here, sterilized equipment is being prepared before being used for a surgery.
Blog
Blog |
10 April 2021
Antimicrobial resistance

Managing antimicrobial resistance amid COVID-19 is a challenge

In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.
Blog
Blog |
23 March 2021
Intellectual property and trade

5 things we learned in taking on big pharma

Tobeka Daki was diagnosed with HER2 positive breast cancer in 2013. She needed a cancer drug made by Roche, trastuzumab. But it was too expensive and patents on the drug blocked the production of any affordable alternatives in South Africa where she lived.
Blog
Blog |
18 January 2021
Intellectual property and trade

Will history repeat itself?

Blog
Blog |
14 January 2021
Vaccines

The Devil is in the Details: A new stockpile for Ebola vaccines

Blog
Blog |
25 December 2020
COVID-19
United Kingdom

Passing exams and planning protests - the role of students in the access to medicines movement

GeneXpert diagnosis machine
Blog
Blog |
02 December 2020
Tuberculosis
Malawi

My Brother’s Keeper: Helping inmates protect themselves and each other from tuberculosis in a prison in Malawi

MSF’s medical staff review patient files during the ward round in the MSF Hospital in the Bentiu Protection of Civilian (PoC) site. Since the COVID-19 pandemic reached South Sudan, MSF has to reduce its inpatient bed capacity to adhere to preventive measures.
Blog
Blog |
05 November 2020
COVID-19

Decolonising medicines and global health: We need genuine and lasting reforms that put patients in the driving seat

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury